Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2025
Enhertu approved in Canada as the first and only HER2 directed therapy for patients with HR positive HER2 low or HER2 ultra low metastatic breast cancer, following disease progression after one or more endocrine therapies
29 October 2025 - Based on the DESTINY-Breast06 Phase 3 trial results demonstrating statistically significant and clinically meaningful progression-free survival ...
Posted by Michael Wonder on 27 Oct 2025
Health Canada grants authorisation for Leqembi (lecanemab) for the treatment of early Alzheimer’s disease
26 October 2025 - Eisai and Biogen announced today that Health Canada has issued a notice of compliance with conditions for ...
Posted by Michael Wonder on 24 Oct 2025
Biocon Biologics receives Health Canada spproval for Yesintek and Yesintek I.V. (ustekinumab), a biosimilar to Stelara
23 October 2025 - Biocon Biologics today announced that Health Canada has granted a notice of compliance for Yesintek (ustekinumab ...
Posted by Michael Wonder on 24 Oct 2025
Apotex receives Health Canada approval for Loqtorzi - the first and only immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer
23 October 2025 - Apotex today announced that Health Canada has granted a notice of compliance for Loqtorzi (toripalimab) for ...
Posted by Michael Wonder on 23 Oct 2025
Dupixent (dupilumab injection) approved in Canada for adults with inadequately controlled chronic obstructive pulmonary disease
22 October 2025 - Health Canada has approved Dupixent (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...
Posted by Michael Wonder on 22 Oct 2025
Lyvdelzi (seladelpar) receives Health Canada approval for the treatment of primary biliary cholangitis
21 October 2025 - Gilead Sciences today announced that Health Canada has approved Lyvdelzi (seladelpar) for the treatment of primary biliary ...
Posted by Michael Wonder on 22 Oct 2025
Pfizer Canada announces Health Canada approval of Abrysvo for adults 18+
21 October 2025 - With the approval of Arbysvo for adults aged 18+, there is now a way to help ...
Posted by Michael Wonder on 16 Oct 2025
Incyte Canada announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis in children ages 2-11
15 October 2025 - First and only topical JAK inhibitor cream approved in Canada for paediatric atopic dermatitis. ...
Posted by Michael Wonder on 07 Oct 2025
Jesse's dad, who walked Canada for his son, cheers approval of new Duchenne drug
3 October 2025 - Vamorolone is the first Health Canada approved drug developed specifically to treat Duchenne. ...
Posted by Michael Wonder on 03 Oct 2025
Health Canada approves Agamree (vamorolone) as the first treatment for Duchenne muscular dystrophy in Canada
2 October 2025 - Kye Pharmaceuticals announced today that Health Canada has approved Agamree (vamorolone) for the treatment of Duchenne muscular ...
Posted by Michael Wonder on 02 Oct 2025
Organon Canada announces the availability of Nduvra (1% tapinarof cream) for the topical treatment of plaque psoriasis in adults
1 October 2025 - Organon Canada announces the availability of Ndruvra (1% tapinarof cream) for the topical treatment of plaque psoriasis ...
Posted by Michael Wonder on 24 Sep 2025
Teva and Medincell’s risperidone LAI approved in Canada as Longavo
23 September 2025 - Teva Canada has received regulatory approval for risperidone long-acting injection from Health Canada for the treatment ...
Posted by Michael Wonder on 20 Sep 2025
Health Canada approves Celltrion’s Stoboclo and Osenvelt (CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia and Xgeva, respectively
18 September 2025 - The approval is based on the totality of evidence including results from a Phase III clinical ...
Posted by Michael Wonder on 11 Sep 2025
Health Canada approves Slenyto - extended-release melatonin formulation - as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome
10 September 2025 - Neurim Pharmaceuticals is pleased to announce that Health Canada has granted marketing authorisation for Slenyto, an ...
Posted by Michael Wonder on 10 Sep 2025
Health Canada approves Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome
9 Settember 2025 - Bylvay is the first and only medication approved in Canada for the treatment of both Alagille ...